Are you interested in seeing more of our antibodies in action? The following three studies have successfully utilized our antibodies to suggest or identify new biomarkers for different human cancers. Keep reading.
1. IgG Fc binding protein (FCGBP) is downregulated in metastatic lesions and predicts survival in metastatic colorectal cancer patients.
In metastatic colorectal cancer, resistance to chemotherapy limits treatment efficacy due to individual differences and drug targets. A new study provides additional clinical biomarkers for prognosis improvement proposing alternative clinical options.
In this study, IgG-binding protein and colorectal cancer biomarker FCGBP are downregulated with disease progression. Additionally, the authors observed the relationship between FCGBP expression and the clinical features of liver metastases of colorectal cancer, showing a connection with better outcomes for patients with liver metastasis.
This study utilized our anti-FCGBP polyclonal antibody (HPA003564) in IHC on FFPE-processed human tumor tissues.
Ref: Yuan Z, Zhao Z, Hu H, Zhu Y, Zhang W, Tang Q, Huang R, Gao F, Zou C, Wang G, Wang X. IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients. Onco Targets Ther. 2021;14:967-977.